Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone303-625-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$95.39 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.89) by $0.17. The biopharmaceutical company earned $37.60 million during the quarter, compared to analyst estimates of $35.84 million. Clovis Oncology had a negative net margin of 298.53% and a negative return on equity of 1,576.32%. Clovis Oncology's quarterly revenue was up 65.2% compared to the same quarter last year. During the same period last year, the business earned ($1.71) EPS. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
How can I listen to Clovis Oncology's earnings call?
Clovis Oncology will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Clovis Oncology issued on next quarter's earnings?
Clovis Oncology issued an update on its fourth quarter 2019
Pre-Market earnings guidance on Tuesday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $38.3-39.3 million, compared to the consensus revenue estimate of $40.39 million.
What price target have analysts set for CLVS?
15 brokerages have issued twelve-month price objectives for Clovis Oncology's shares. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's share price to reach $19.91 in the next year. This suggests a possible upside of 110.9% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. According to Zacks Investment Research, "Clovis reported impressive third-quarter results with earnings and revenues beating estimates. Market share of Clovis’ Rubraca in the ovarian cancer PARP inhibitor market improved in the first half. Approval in second-line maintenance setting for ovarian cancer irrespective of the BRCA-mutation is a positive. Successful development of Rubraca in several ongoing studies, targeting different types of ovarian cancer patients, is likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several others under development." (11/27/2019)
- 2. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019)
- 3. JPMorgan Chase & Co. analysts commented, "Clovis’ 4Q report was as expected following the top-line pre-announcement at The J.P. Morgan Healthcare Conference. Importantly, all key Rubraca clinical trials remain on track with the next material data updates likely at ESMO in September. In the meantime, we expect investors to continue to focus on the strategic value of the company, particularly in the wake of the GSK/TSRO deal. We are also increasingly asked about CLVS’s cash outlook given an accelerating operating spend and a first round of converts due in 2021 (~$284M). While these questions are likely to persist, we anticipate they will be secondary to the company’s strategic potential." (2/27/2019)
Has Clovis Oncology been receiving favorable news coverage?
Media coverage about CLVS stock has been trending very negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Clovis Oncology earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Clovis Oncology.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of Clovis Oncology own?
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (9.23%), State Street Corp (6.68%), Candriam Luxembourg S.C.A. (1.82%), Pinnacle Associates Ltd. (1.15%), Charles Schwab Investment Management Inc. (0.58%) and California Public Employees Retirement System (0.44%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Panagora Asset Management Inc., Bank of New York Mellon Corp, First Midwest Bank Trust Division, Candriam Luxembourg S.C.A., KBC Group NV, Janney Montgomery Scott LLC and Jacobs Levy Equity Management Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Paul Edward Gross. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
CLVS stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Pinnacle Associates Ltd., Palo Alto Investors LP, California Public Employees Retirement System, Rafferty Asset Management LLC, Creative Planning, Nisa Investment Advisors LLC and Alpine Global Management LLC. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $9.44.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $517.41 million and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis. View Additional Information About Clovis Oncology.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
